Cargando…

Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves

IMPORTANCE: Seroprevalence studies inform the extent of infection and assist evaluation of mitigation strategies for the COVID-19 pandemic. OBJECTIVE: To estimate the prevalence of unidentified SARS-CoV-2 infection in the general population of Hong Kong. DESIGN, SETTING, AND PARTICIPANTS: A prospect...

Descripción completa

Detalles Bibliográficos
Autores principales: Boon, Siaw S., Wong, Martin C. S., Ng, Rita W. Y., Leung, Danny T. M., Chen, Zigui, Lai, Christopher K. C., Ho, Wendy C. S., Huang, Junjie, Wong, Barry K. C., Fung, Kitty S. C., Chan, Paul K. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593764/
https://www.ncbi.nlm.nih.gov/pubmed/34779848
http://dx.doi.org/10.1001/jamanetworkopen.2021.32923
_version_ 1784599823802957824
author Boon, Siaw S.
Wong, Martin C. S.
Ng, Rita W. Y.
Leung, Danny T. M.
Chen, Zigui
Lai, Christopher K. C.
Ho, Wendy C. S.
Huang, Junjie
Wong, Barry K. C.
Fung, Kitty S. C.
Chan, Paul K. S.
author_facet Boon, Siaw S.
Wong, Martin C. S.
Ng, Rita W. Y.
Leung, Danny T. M.
Chen, Zigui
Lai, Christopher K. C.
Ho, Wendy C. S.
Huang, Junjie
Wong, Barry K. C.
Fung, Kitty S. C.
Chan, Paul K. S.
author_sort Boon, Siaw S.
collection PubMed
description IMPORTANCE: Seroprevalence studies inform the extent of infection and assist evaluation of mitigation strategies for the COVID-19 pandemic. OBJECTIVE: To estimate the prevalence of unidentified SARS-CoV-2 infection in the general population of Hong Kong. DESIGN, SETTING, AND PARTICIPANTS: A prospective cross-sectional study was conducted in Hong Kong after each major wave of the COVID-19 pandemic (April 21 to July 7, 2020; September 29 to November 23, 2020; and January 15 to April 18, 2021). Adults (age ≥18 years) who had not been diagnosed with COVID-19 were recruited during each period, and their sociodemographic information, symptoms, travel, contact, quarantine, and COVID-19 testing history were collected. MAIN OUTCOMES AND MEASURES: The main outcome was prevalence of SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies were detected by an enzyme-linked immunosorbent assay based on spike (S1/S2) protein, followed by confirmation with a commercial electrochemiluminescence immunoassay based on the receptor binding domain of spike protein. RESULTS: The study enrolled 4198 participants (2539 [60%] female; median age, 50 years [IQR, 25 years]), including 903 (22%), 1046 (25%), and 2249 (53%) during April 21 to July 7, 2020; during September 29 to November 23, 2020; and during January 15 to April 18, 2021, respectively. The numbers of participants aged 18 to 39 years, 40 to 59 years, and 60 years or older were 1328 (32%), 1645 (39%), and 1225 (29%), respectively. Among the participants, 2444 (58%) stayed in Hong Kong since November 2019 and 2094 (50%) had negative SARS-CoV-2 RNA test results. Only 170 (4%) reported ever having contact with individuals with confirmed cases, and 5% had been isolated or quarantined. Most (2803 [67%]) did not recall any illnesses, whereas 737 (18%), 212 (5%), and 385 (9%) had experienced respiratory symptoms, gastrointestinal symptoms, or both, respectively, before testing. Six participants were confirmed to be positive for anti-SARS-CoV-2 IgG; the adjusted prevalence of unidentified infection was 0.15% (95% CI, 0.06%-0.32%). Extrapolating these findings to the whole population, there were fewer than 1.9 unidentified infections for every recorded confirmed case. The overall prevalence of SARS-CoV-2 infection in Hong Kong before the roll out of vaccination was less than 0.45%. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of participants from the general public in Hong Kong, the prevalence of unidentified SARS-CoV-2 infection was low after 3 major waves of the pandemic, suggesting the success of the pandemic mitigation by stringent isolation and quarantine policies even without complete city lockdown. More than 99.5% of the general population of Hong Kong remain naive to SARS-CoV-2, highlighting the urgent need to achieve high vaccine coverage.
format Online
Article
Text
id pubmed-8593764
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher American Medical Association
record_format MEDLINE/PubMed
spelling pubmed-85937642021-11-24 Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves Boon, Siaw S. Wong, Martin C. S. Ng, Rita W. Y. Leung, Danny T. M. Chen, Zigui Lai, Christopher K. C. Ho, Wendy C. S. Huang, Junjie Wong, Barry K. C. Fung, Kitty S. C. Chan, Paul K. S. JAMA Netw Open Original Investigation IMPORTANCE: Seroprevalence studies inform the extent of infection and assist evaluation of mitigation strategies for the COVID-19 pandemic. OBJECTIVE: To estimate the prevalence of unidentified SARS-CoV-2 infection in the general population of Hong Kong. DESIGN, SETTING, AND PARTICIPANTS: A prospective cross-sectional study was conducted in Hong Kong after each major wave of the COVID-19 pandemic (April 21 to July 7, 2020; September 29 to November 23, 2020; and January 15 to April 18, 2021). Adults (age ≥18 years) who had not been diagnosed with COVID-19 were recruited during each period, and their sociodemographic information, symptoms, travel, contact, quarantine, and COVID-19 testing history were collected. MAIN OUTCOMES AND MEASURES: The main outcome was prevalence of SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies were detected by an enzyme-linked immunosorbent assay based on spike (S1/S2) protein, followed by confirmation with a commercial electrochemiluminescence immunoassay based on the receptor binding domain of spike protein. RESULTS: The study enrolled 4198 participants (2539 [60%] female; median age, 50 years [IQR, 25 years]), including 903 (22%), 1046 (25%), and 2249 (53%) during April 21 to July 7, 2020; during September 29 to November 23, 2020; and during January 15 to April 18, 2021, respectively. The numbers of participants aged 18 to 39 years, 40 to 59 years, and 60 years or older were 1328 (32%), 1645 (39%), and 1225 (29%), respectively. Among the participants, 2444 (58%) stayed in Hong Kong since November 2019 and 2094 (50%) had negative SARS-CoV-2 RNA test results. Only 170 (4%) reported ever having contact with individuals with confirmed cases, and 5% had been isolated or quarantined. Most (2803 [67%]) did not recall any illnesses, whereas 737 (18%), 212 (5%), and 385 (9%) had experienced respiratory symptoms, gastrointestinal symptoms, or both, respectively, before testing. Six participants were confirmed to be positive for anti-SARS-CoV-2 IgG; the adjusted prevalence of unidentified infection was 0.15% (95% CI, 0.06%-0.32%). Extrapolating these findings to the whole population, there were fewer than 1.9 unidentified infections for every recorded confirmed case. The overall prevalence of SARS-CoV-2 infection in Hong Kong before the roll out of vaccination was less than 0.45%. CONCLUSIONS AND RELEVANCE: In this cross-sectional study of participants from the general public in Hong Kong, the prevalence of unidentified SARS-CoV-2 infection was low after 3 major waves of the pandemic, suggesting the success of the pandemic mitigation by stringent isolation and quarantine policies even without complete city lockdown. More than 99.5% of the general population of Hong Kong remain naive to SARS-CoV-2, highlighting the urgent need to achieve high vaccine coverage. American Medical Association 2021-11-15 /pmc/articles/PMC8593764/ /pubmed/34779848 http://dx.doi.org/10.1001/jamanetworkopen.2021.32923 Text en Copyright 2021 Boon SS et al. JAMA Network Open. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License.
spellingShingle Original Investigation
Boon, Siaw S.
Wong, Martin C. S.
Ng, Rita W. Y.
Leung, Danny T. M.
Chen, Zigui
Lai, Christopher K. C.
Ho, Wendy C. S.
Huang, Junjie
Wong, Barry K. C.
Fung, Kitty S. C.
Chan, Paul K. S.
Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title_full Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title_fullStr Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title_full_unstemmed Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title_short Seroprevalence of Unidentified SARS-CoV-2 Infection in Hong Kong During 3 Pandemic Waves
title_sort seroprevalence of unidentified sars-cov-2 infection in hong kong during 3 pandemic waves
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593764/
https://www.ncbi.nlm.nih.gov/pubmed/34779848
http://dx.doi.org/10.1001/jamanetworkopen.2021.32923
work_keys_str_mv AT boonsiaws seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT wongmartincs seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT ngritawy seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT leungdannytm seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT chenzigui seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT laichristopherkc seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT howendycs seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT huangjunjie seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT wongbarrykc seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT fungkittysc seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves
AT chanpaulks seroprevalenceofunidentifiedsarscov2infectioninhongkongduring3pandemicwaves